A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
Taƙaitaccen labari
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
Bi sabbin labarai daga amintattun mawallafa tare da taƙaitaccen bayani. Buɗe mahaɗin tushe na asali don cikakken bayani.